Blincyto 38.5 mcg for acute lymphoblastic leukemia

 Blincyto (blinatumomab) is a medication used to treat a specific type of blood cancer called Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

The dose of  Blincyto is based on the patient's weight and is given as a continuous intravenous infusion. The recommended starting dose for adults is 9 mcg/day, which is gradually increased over several days to a target dose of 28 mcg/day. The maximum dose is 42 mcg/day.

However, you mentioned 38.5 mcg," which is not a standard dosage for Blincyto. It's possible that you made a mistake in your question or that you have been prescribed a different dosage based on your individual circumstances.

In any case, it's important to follow your healthcare provider's instructions regarding the dose and administration of Blincyto or any other medication.

BLINCYTO TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA

Blinatumomab (brand name Blincyto) is a medication used to treat a specific type of acute lymphoblastic leukemia (ALL) called Philadelphia chromosome-negative B-cell precursor ALL. Blinatumomab is a type of immunotherapy called a bispecific T-cell engager (BiTE) that works by connecting T-cells to cancer cells, which can help the immune system identify and destroy cancer cells.

Blinatumomab is given as an intravenous infusion over a period of four weeks, followed by a two-week break, and then another four-week infusion cycle. Treatment typically lasts for a total of six cycles. The medication is given in a hospital or infusion center, and patients are closely monitored for potential side effects.

Common side effects of Blinatumomab include fever, fatigue, headache, nausea, vomiting, diarrhea, and decreased appetite. More serious side effects can include infections, allergic reactions, neurological problems, and cytokine release syndrome, which is a potentially life-threatening immune response. Patients receiving Blinatumomab may also experience low levels of certain blood cells, which can increase the risk of bleeding or infections.

Blinatumomab can be a highly effective treatment for certain ALL types, but it is not suitable for everyone. It is important to discuss the potential risks and benefits of this medication with your doctor to determine if it is the right treatment for you.